Pashtoon Kasi: Positive thing to look at ASCO each year is the “incremental” gains in survival
Pashtoon Kasi, Medical Director of GI Medical Oncology at City of Hope, shared a post on X:
“Positive thing to look at ASCO each year is the “incremental” gains in survival for our patients with MSS colorectal cancer. A few years ago I started seeing survivals >40+ months. This year I’m seeing >50-52 months. For MSI, “not reached” is a recurring theme.”
Mark Lewis, Director of Gastrointestinal Oncology at Intermountain Healthcare in Utah,shared a post by Pashtoon Kasi, on X, adding:
“Unpopular opinion (?) but as progress marches on we need to re-evaluate just how long we should keep patients on oxaliplatin, especially with more therapeutic options becoming available In my own clinic I almost never give more than 8 cycles (85mg/m^2) in the mCRC setting.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023